VisionPoint Advisory Group’s United Therapeutics UTHR Stock Holding History

VisionPoint Advisory Group’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$618K	Sell	1,141 -68	-6%	-$35.2K	0.1%	208
2026 Q2	$655K	Sell	1,209 -32	-3%	-$18K	0.11%	210
2026 Q1	$736K	Sell	1,241 -146	-11%	-$72.7K	0.14%	170
2025 Q4	$676K	Buy	1,387 +238	+21%	+$111K	0.13%	172
2025 Q3	$482K	Sell	1,149 -158	-12%	-$53.1K	0.1%	212
2025 Q2	$376K	Buy	+1,307	New	+$391K	0.08%	231

Other funds holding UTHR

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return

Polaris Capital Management Boston, Massachusetts $953M AUM 27.74% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

Livforsakringsbolaget Skandia Stockholm, Sweden $3.02B AUM 43.19% 1-Year Est. Return

Nepsis Inc Minneapolis, Minnesota $317M AUM 37.22% 1-Year Est. Return

Vilga Financial Planning Fair Lawn, New Jersey $168M AUM 23.03% 1-Year Est. Return

VisionPoint Advisory Group's UTHR Position: Q3 2026 in Review

VisionPoint Advisory Group reduced its United Therapeutics (UTHR) stake by 5.6% in Q3 2026, selling an estimated $35.2K and leaving 1,141 shares worth $618K. The position accounts for 0.1% of the portfolio, ranked #208.

VisionPoint Advisory Group first reported a position in UTHR in Q2 2025 and has held it in 6 quarters since. The position peaked at $736K in Q1 2026. 137 funds tracked by Wall St. Rank hold UTHR as of Q3 2026.

VisionPoint Advisory Group held 1,141 shares of United Therapeutics worth $618K as of Q3 2026.
VisionPoint Advisory Group sold 68 United Therapeutics shares in Q3 2026, an estimated $35.2K.
United Therapeutics made up 0.1% of VisionPoint Advisory Group's portfolio in Q3 2026, its #208 holding.
VisionPoint Advisory Group first reported a position in United Therapeutics in Q2 2025 and has held it in 6 quarters since.
VisionPoint Advisory Group's United Therapeutics position peaked at $736K in Q1 2026.
137 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2026.

Based on VisionPoint Advisory Group's 13F filing for Q3 2026, filed 9 Oct 2026.